Development and Characterization of Pepducins as Gs-biased Allosteric Agonists*♦

Background: A Gs-biased agonist for the β2-adrenergic receptor (β2AR) has yet to be reported. Results: A screen of β2AR pepducins identified receptor-dependent and receptor-independent pepducins that selectively activate Gs. Conclusion: Receptor-dependent pepducins promote a Gs-biased conformation of the β2AR, whereas receptor-independent pepducins directly activate Gs. Significance: Gs-biased pepducins provide a valuable tool for the continued study of β2AR function and may prove useful as next-generation asthma therapeutics. The β2-adrenergic receptor (β2AR) is a prototypical G protein-coupled receptor that mediates many hormonal responses, including cardiovascular and pulmonary function. β-Agonists used to combat hypercontractility in airway smooth muscle stimulate β2AR-dependent cAMP production that ultimately promotes airway relaxation. Chronic stimulation of the β2AR by long acting β-agonists used in the treatment of asthma can promote attenuated responsiveness to agonists and an increased frequency of fatal asthmatic attacks. β2AR desensitization to β-agonists is primarily mediated by G protein-coupled receptor kinases and β-arrestins that attenuate receptor-Gs coupling and promote β2AR internalization and degradation. A biased agonist that can selectively stimulate Gs signaling without promoting receptor interaction with G protein-coupled receptor kinases and β-arrestins should serve as an advantageous asthma therapeutic. To identify such molecules, we screened ∼50 lipidated peptides derived from the intracellular loops of the β2AR, known as pepducins. This screen revealed two classes of Gs-biased pepducins, receptor-independent and receptor-dependent, as well as several β-arrestin-biased pepducins. The receptor-independent Gs-biased pepducins operate by directly stimulating G protein activation. In contrast, receptor-dependent Gs-biased pepducins appear to stabilize a Gs-biased conformation of the β2AR that couples to Gs but does not undergo G protein-coupled receptor kinase-mediated phosphorylation or β-arrestin-mediated internalization. Functional studies in primary human airway smooth muscle cells demonstrate that Gs-biased pepducins are not subject to conventional desensitization and thus may be good candidates for the development of next generation asthma therapeutics. Our study reports the first Gs-biased activator of the β2AR and provides valuable tools for the study of β2AR function.

[1]  J. Benovic,et al.  Visualization of Agonist-induced Sequestration and Down-regulation of a Green Fluorescent Protein-tagged β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[2]  E.,et al.  Inverse Agonist Activity of 3-Adrenergic Antagonists , 2005 .

[3]  S. Hill,et al.  Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling , 2011, Trends in pharmacological sciences.

[4]  Hak Jung Kim,et al.  Activation of human monocytes by a formyl peptide receptor 2‐derived pepducin , 2010, FEBS letters.

[5]  J. Friedman,et al.  Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. , 2004, Molecular pharmacology.

[6]  Pallavi Sachdev,et al.  Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells , 2010, Proceedings of the National Academy of Sciences.

[7]  Xavier Deupi,et al.  The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex , 2009, Proceedings of the National Academy of Sciences.

[8]  G. Feuerstein,et al.  Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. , 1992, Cardiovascular research.

[9]  R. Ruffolo,et al.  Cardioprotective potential of carvedilol. , 1993, Cardiology.

[10]  P. Cooper,et al.  20-HETE Mediates Ozone-Induced, Neutrophil-Independent Airway Hyper-Responsiveness in Mice , 2010, PloS one.

[11]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[12]  D. Deshpande,et al.  β‐Arrestins specifically constrain β2‐adrenergic receptor signaling and function in airway smooth muscle , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Robert J. Lefkowitz,et al.  β-Arrestin-biased Agonism at the β2-Adrenergic Receptor* , 2008, Journal of Biological Chemistry.

[14]  Robert J. Lefkowitz,et al.  A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.

[15]  R. Schellenberg,et al.  Nebivolol and Metoprolol for Treating Migraine: An Advance on β‐Blocker Treatment? , 2007, Headache.

[16]  Mark S Levenson,et al.  Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor Agonists , 2011, Pediatrics.

[17]  A. Kuliopulos,et al.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation , 2002, Nature Medicine.

[18]  P. Chidiac,et al.  Inverse agonist activity of beta-adrenergic antagonists. , 1994, Molecular pharmacology.

[19]  Kurt Wüthrich,et al.  Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.

[20]  D. Deshpande,et al.  Targeting G protein-coupled receptor signaling in asthma. , 2006, Cellular signalling.

[21]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[22]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[23]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[24]  R. Panettieri,et al.  A human airway smooth muscle cell line that retains physiological responsiveness. , 1989, The American journal of physiology.

[25]  J. Benovic,et al.  Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle. , 1998, American journal of respiratory cell and molecular biology.

[26]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[27]  M. Caron,et al.  beta-Arrestin: a protein that regulates beta-adrenergic receptor function. , 1990, Science.

[28]  Ryan T. Strachan,et al.  Regulation of Beta-2-Adrenergic Receptor Function by Conformationally Selective Single-domain Intrabodies , 2013 .

[29]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[30]  Xavier Deupi,et al.  Coupling ligand structure to specific conformational switches in the β2-adrenoceptor , 2006, Nature chemical biology.

[31]  B. Kobilka,et al.  Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor. , 2012, Structure.

[32]  D. Schwartz,et al.  Beta-arrestin-2 regulates the development of allergic asthma. , 2003, The Journal of clinical investigation.

[33]  David J. Vaughan,et al.  Role of the G Protein-coupled Receptor Kinase Site Serine Cluster in β2-Adrenergic Receptor Internalization, Desensitization, and β-Arrestin Translocation* , 2006, Journal of Biological Chemistry.

[34]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[35]  Albert C. Pan,et al.  Activation mechanism of the β2-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.

[36]  J. Pelletier,et al.  High-Throughput Screening of G Protein-Coupled Receptor Antagonists Using a Bioluminescence Resonance Energy Transfer 1-Based β-Arrestin2 Recruitment Assay , 2005, Journal of biomolecular screening.

[37]  Albert C. Pan,et al.  The Dynamic Process of β2-Adrenergic Receptor Activation , 2013, Cell.

[38]  C. Strader,et al.  Specific activation of Gs by synthetic peptides corresponding to an intracellular loop of the β‐adrenergic receptor , 1991, FEBS letters.

[39]  R. Lefkowitz,et al.  Seven transmembrane receptors: something old, something new , 2007, Acta physiologica.

[40]  Michel Bouvier,et al.  Probing the activation-promoted structural rearrangements in preassembled receptor–G protein complexes , 2006, Nature Structural &Molecular Biology.

[41]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[42]  D. Schwartz,et al.  Both hematopoietic-derived and non-hematopoietic-derived {beta}-arrestin-2 regulates murine allergic airway disease. , 2010, American journal of respiratory cell and molecular biology.

[43]  Pascale G. Charest,et al.  β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Arthur Christopoulos,et al.  Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.

[45]  Ryan T. Strachan,et al.  Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.

[46]  J. Benovic,et al.  Role of β-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. , 2014, Current opinion in cell biology.

[47]  J. Benovic,et al.  Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein , 2013, Proceedings of the National Academy of Sciences.

[48]  A. Kuliopulos,et al.  Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug Development* , 2012, The Journal of Biological Chemistry.

[49]  B. J. Knoll,et al.  Salmeterol‐induced desensitization, internalization and phosphorylation of the human β2‐adrenoceptor , 1998, British journal of pharmacology.

[50]  S. Tobe,et al.  Contemporary use of β-blockers: clinical relevance of subclassification. , 2014, The Canadian journal of cardiology.

[51]  L. Luttrell.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. , 2014, Molecular endocrinology.

[52]  S. Ben‐Sasson,et al.  Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). , 2003, Blood.

[53]  N. Kaneider,et al.  Reversing systemic inflammatory response syndrome with chemokine receptor pepducins , 2005, Nature Medicine.

[54]  Margarita C Theodoropoulou,et al.  Interactions of the α-subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: a critical review and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic potentials. , 2013, Journal of structural biology.

[55]  B. Kobilka,et al.  Subtype-Specific Intracellular Trafficking of α2-Adrenergic Receptors , 1997 .

[56]  Michel Bouvier,et al.  Real-time monitoring of receptor and G-protein interactions in living cells , 2005, Nature Methods.

[57]  L. Pulakat,et al.  The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist , 2013, PloS one.

[58]  A. Kuliopulos,et al.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Cazzola,et al.  β2‐adrenoceptor agonists: current and future direction , 2011, British journal of pharmacology.

[60]  M. Dean,et al.  Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. , 2007, Journal of medicinal chemistry.